Burn injuries, trauma, and surgical procedures can give rise to exuberant scarring, which can lead to physical disability and to patients being stigmatized by their disfigurement. In a review article in this week's PLoS Medicine, Geoffrey Gurtner (Department of Surgery, Stanford University School of Medicine) and colleagues examine the process of such hypertrophic scar formation, the results of current treatments, and the research areas that are likely to lead to advances in the field.
Annually, over 1 million people require treatment for burns in the United States, 2 million are injured in motor vehicle accidents, and over 34 million related surgical procedures are performed. Although the incidence of hypertrophic scarring following these types of injuries is not known, say the authors, "it is a common outcome that creates a problem of enormous magnitude. Treatment of these cases is estimated to cost at least $4 billion per annum in the US alone." And the incidence of burns and traumatic injuries is even greater in the developing world.
Citation: Aarabi S, Longaker MT, Gurtner GC (2007)
Hypertrophic scar formation following burns and trauma: New approaches to treatment. PLoS Med 4(9): e234.
Click here for access to the published paper
CONTACT:
Geoffrey Gurtner
Stanford University School of Medicine
257 Campus Drive West
Mayer Building #GK210
Stanford, CA 94305
United States of America
About PLoS Medicine
PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues. For more information, visit plosmedicine/
About the Public Library of Science
The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit plos/
четверг, 23 июня 2011 г.
среда, 22 июня 2011 г.
Steroids Are Abused For Skin, Not Just Muscles
Steroids have been in the
press lately and given a bad name for abuse. There must be reasons why
people use steroid products on a regular basis and don't know it. Our skin
is the largest organ of the human body, and it needs to stay healthy. Most
dermatologists treat the 15 million chronic skin patients in the US with
steroids, without the patient ever knowing.
Consistent steroid use for skin problems can result in thinning of the
skin, allergies, resistance to steroid therapy and even Cushing's disease
(a consistent redness caused by capillary blockage).
Seagate Medical has launched a new natural skin care drug called epizyn
(epizyn) that consists primarily of zinc gluconate. It is a
unique patented broad spectrum gel and spray topical that penetrates skin
on a cellular level to help relieve chronic skin conditions such as
pruritis (itchy skin), burns, redness, acne, rashes (especially diaper
rash), dry skin, psoriasis, and eczema (atopic dermatitis). It is a natural
healing agent that is also great for wounds and greatly reducing scarring.
It can even be used around the eyes.
"Epizyn is the greatest thing I have ever used," said Bill Smith of
Fayette, MO.
Unlike other zinc skin treatments, including zinc pyrithione and zinc
oxide, epizyn offers greater bio-availability and pharmacokinetic
properties, offering increased systemic circulation to rapidly assist in
the body's natural capability to restore skin back to its natural state.
Most do not know that 20% of zinc in the human body is contained in the
skin.
Originally, the epizyn compound was successfully used for treating skin
conditions on numerous animal species including lacerations and even
serious snake bites on horses. Those treating the animals could not believe
the amazing effects it had on their own skin and word got out to
dermatologists that the compound worked to heal the animal owners' skin
conditions just as well. Now it is the fastest-growing natural skin care
product on the market. Sold through dermatologists and the Internet, epizyn
is the only non-steroidal zinc gluconate available on the market.
About Seagate Medical, Inc.
Seagate Medical was founded on the principal of developing natural
treatments with high efficacy and low cost. (In fact they offer discounts
to their clients for future orders and huge breaks to practicing
physicians.) "Our mission is to provide medical products to treat chronic
conditions without fear of side effects," said Maureen Kelley, a licensed
esthetician who is employed by Seagate Medical.
Seagate Medical, Inc.
epizyn
press lately and given a bad name for abuse. There must be reasons why
people use steroid products on a regular basis and don't know it. Our skin
is the largest organ of the human body, and it needs to stay healthy. Most
dermatologists treat the 15 million chronic skin patients in the US with
steroids, without the patient ever knowing.
Consistent steroid use for skin problems can result in thinning of the
skin, allergies, resistance to steroid therapy and even Cushing's disease
(a consistent redness caused by capillary blockage).
Seagate Medical has launched a new natural skin care drug called epizyn
(epizyn) that consists primarily of zinc gluconate. It is a
unique patented broad spectrum gel and spray topical that penetrates skin
on a cellular level to help relieve chronic skin conditions such as
pruritis (itchy skin), burns, redness, acne, rashes (especially diaper
rash), dry skin, psoriasis, and eczema (atopic dermatitis). It is a natural
healing agent that is also great for wounds and greatly reducing scarring.
It can even be used around the eyes.
"Epizyn is the greatest thing I have ever used," said Bill Smith of
Fayette, MO.
Unlike other zinc skin treatments, including zinc pyrithione and zinc
oxide, epizyn offers greater bio-availability and pharmacokinetic
properties, offering increased systemic circulation to rapidly assist in
the body's natural capability to restore skin back to its natural state.
Most do not know that 20% of zinc in the human body is contained in the
skin.
Originally, the epizyn compound was successfully used for treating skin
conditions on numerous animal species including lacerations and even
serious snake bites on horses. Those treating the animals could not believe
the amazing effects it had on their own skin and word got out to
dermatologists that the compound worked to heal the animal owners' skin
conditions just as well. Now it is the fastest-growing natural skin care
product on the market. Sold through dermatologists and the Internet, epizyn
is the only non-steroidal zinc gluconate available on the market.
About Seagate Medical, Inc.
Seagate Medical was founded on the principal of developing natural
treatments with high efficacy and low cost. (In fact they offer discounts
to their clients for future orders and huge breaks to practicing
physicians.) "Our mission is to provide medical products to treat chronic
conditions without fear of side effects," said Maureen Kelley, a licensed
esthetician who is employed by Seagate Medical.
Seagate Medical, Inc.
epizyn
вторник, 21 июня 2011 г.
Senetek PLC Announces Positive Results From Pyratine-6(TM) Clinical Trial In Patients With Acne Rosacea
Senetek PLC (OTC Bulletin
Board: SNKTY), a Life Sciences company engaged in the development of
technologies that target the science of healthy aging, announced
positive study results from a clinical trial of Pyratine-6(TM) in patients
with acne rosacea. The findings have been accepted for presentation at the
International Investigative Congress of Dermatology at its May 2008 meeting
in Kyoto, Japan.
Based on positive results demonstrated in previous studies of
Pyratine-6(TM) (0.1%), for the remediation of photodamaged skin and
erythema which included unprecedented reduction in facial redness, in as
early as two weeks, an additional study was initiated for acne rosacea. The
follow up study was designed to extend these significant clinical findings
by assessing the effects of Pyratine-6(TM) (0.125%) in improving clinical
signs and symptoms of acne rosacea. Twenty-four subjects with
mild-to-moderate acne rosacea participated in the 12 week study. Subjects
were evaluated at baseline, 4, 8 and 12 weeks. Evaluations included
physician assessments of inflammatory lesion count, severity of erythema
and telangiectasia, and overall clinical improvement. Patient assessments
of signs and symptoms of rosacea and skin tolerance were also rated at each
follow-up. In addition, transepidermal water loss measurements and facial
photography were conducted at each visit.
Pyratine-6(TM) produced a progressive decrease in the symptoms
associated with rosacea including redness and acne lesions. All subject
self-assessments showed good tolerability and cosmetic acceptability. After
12 weeks there was overall clinical improvement in 80% of subjects,
including reduction of erythema and papules. Transepidermal water loss
measurements showed a 22% decrease in water loss, which supports an
improvement in skin barrier function. In view of the promising results, the
current study has been extended to 48 weeks.
Rosacea is a common chronic facial dermatosis, affecting 14 million
Americans, that is characterized by persistent erythema, telangiectasia,
papules and pustules. Patients with rosacea are often unable to tolerate
extended treatment periods with topical agents as a result of skin
sensitivity that accompanies rosacea. Due to the chronic nature of rosacea,
there is a continuing need for efficacious treatments that provide
sustained relief of its principal signs and symptoms.
Dr. Arisa Ortiz from the University of California Irvine, who is
presenting the results of this study at the 2008 International
Investigative Dermatology meeting in Kyoto, Japan, stated, "All study
subjects reported good tolerability and cosmetic acceptability to
Pyratine-6 (TM). The majority of subjects showed reductions in erythema,
papules, burning, stinging, and dryness, all of which are signs and
symptoms associated with acne rosacea. Transepidermal water loss
measurements showed a decrease in water loss which supports an improvement
in skin barrier function, attesting to the moisturizing properties of this
compound."
Commenting on these findings, Frank Massino, Senetek Chairman and Chief
Executive Officer stated, "We are pleased by the positive study findings as
this further confirms the excellent safety and effectiveness profile of
Pyratine-6(TM). Response to Pyratine-6(TM) in the U.S. physician market has
been outstanding and we look forward to expanding our sales and marketing
efforts to accommodate increasing demand for this important product."
About Senetek PLC
Senetek PLC (OTCBB: SNKTY) is a Life Sciences company engaged in the
development of breakthrough technologies that target the science of healthy
aging. The Company's extensive research collaborations have resulted in a
strong pipeline of patented compounds and products with broad therapeutic
applications and a leading presence in dermatology. Senetek collaborates
with established specialty pharmaceutical companies in the final
development and marketing of its proprietary products, most recently
resulting in the development of the best-selling anti-aging product sold in
the North American physician market.
For more information, visit the company's website at
senetekplc.
This news release contains statements that may be considered
'forward-looking statements' within the meaning of the Private Securities
Litigation Reform Act. Forward-looking statements by their nature involve
substantial uncertainty, and actual results may differ materially from
those that might be suggested by such statements. Important factors
identified by the Company that it believes could result in such material
differences are described in the Company's Annual Report on Form 10-K for
the year 2007. However, the Company necessarily can give no assurance that
it has identified or will identify all of the factors that may result in
any particular forward-looking statement materially differing from actual
results, and the Company assumes no obligation to correct or update any
forward-looking statements which may prove to be inaccurate, whether as a
result of new information, future events or otherwise.
Senetek, PLC
senetekplc
Board: SNKTY), a Life Sciences company engaged in the development of
technologies that target the science of healthy aging, announced
positive study results from a clinical trial of Pyratine-6(TM) in patients
with acne rosacea. The findings have been accepted for presentation at the
International Investigative Congress of Dermatology at its May 2008 meeting
in Kyoto, Japan.
Based on positive results demonstrated in previous studies of
Pyratine-6(TM) (0.1%), for the remediation of photodamaged skin and
erythema which included unprecedented reduction in facial redness, in as
early as two weeks, an additional study was initiated for acne rosacea. The
follow up study was designed to extend these significant clinical findings
by assessing the effects of Pyratine-6(TM) (0.125%) in improving clinical
signs and symptoms of acne rosacea. Twenty-four subjects with
mild-to-moderate acne rosacea participated in the 12 week study. Subjects
were evaluated at baseline, 4, 8 and 12 weeks. Evaluations included
physician assessments of inflammatory lesion count, severity of erythema
and telangiectasia, and overall clinical improvement. Patient assessments
of signs and symptoms of rosacea and skin tolerance were also rated at each
follow-up. In addition, transepidermal water loss measurements and facial
photography were conducted at each visit.
Pyratine-6(TM) produced a progressive decrease in the symptoms
associated with rosacea including redness and acne lesions. All subject
self-assessments showed good tolerability and cosmetic acceptability. After
12 weeks there was overall clinical improvement in 80% of subjects,
including reduction of erythema and papules. Transepidermal water loss
measurements showed a 22% decrease in water loss, which supports an
improvement in skin barrier function. In view of the promising results, the
current study has been extended to 48 weeks.
Rosacea is a common chronic facial dermatosis, affecting 14 million
Americans, that is characterized by persistent erythema, telangiectasia,
papules and pustules. Patients with rosacea are often unable to tolerate
extended treatment periods with topical agents as a result of skin
sensitivity that accompanies rosacea. Due to the chronic nature of rosacea,
there is a continuing need for efficacious treatments that provide
sustained relief of its principal signs and symptoms.
Dr. Arisa Ortiz from the University of California Irvine, who is
presenting the results of this study at the 2008 International
Investigative Dermatology meeting in Kyoto, Japan, stated, "All study
subjects reported good tolerability and cosmetic acceptability to
Pyratine-6 (TM). The majority of subjects showed reductions in erythema,
papules, burning, stinging, and dryness, all of which are signs and
symptoms associated with acne rosacea. Transepidermal water loss
measurements showed a decrease in water loss which supports an improvement
in skin barrier function, attesting to the moisturizing properties of this
compound."
Commenting on these findings, Frank Massino, Senetek Chairman and Chief
Executive Officer stated, "We are pleased by the positive study findings as
this further confirms the excellent safety and effectiveness profile of
Pyratine-6(TM). Response to Pyratine-6(TM) in the U.S. physician market has
been outstanding and we look forward to expanding our sales and marketing
efforts to accommodate increasing demand for this important product."
About Senetek PLC
Senetek PLC (OTCBB: SNKTY) is a Life Sciences company engaged in the
development of breakthrough technologies that target the science of healthy
aging. The Company's extensive research collaborations have resulted in a
strong pipeline of patented compounds and products with broad therapeutic
applications and a leading presence in dermatology. Senetek collaborates
with established specialty pharmaceutical companies in the final
development and marketing of its proprietary products, most recently
resulting in the development of the best-selling anti-aging product sold in
the North American physician market.
For more information, visit the company's website at
senetekplc.
This news release contains statements that may be considered
'forward-looking statements' within the meaning of the Private Securities
Litigation Reform Act. Forward-looking statements by their nature involve
substantial uncertainty, and actual results may differ materially from
those that might be suggested by such statements. Important factors
identified by the Company that it believes could result in such material
differences are described in the Company's Annual Report on Form 10-K for
the year 2007. However, the Company necessarily can give no assurance that
it has identified or will identify all of the factors that may result in
any particular forward-looking statement materially differing from actual
results, and the Company assumes no obligation to correct or update any
forward-looking statements which may prove to be inaccurate, whether as a
result of new information, future events or otherwise.
Senetek, PLC
senetekplc
понедельник, 20 июня 2011 г.
People Are Concerned About Skin Cancer Yet They May Not Understand The Risks Of Sun Exposure Or Indoor Tanning
When it comes to tanning, dermatologists have long suspected that most people need an attitude adjustment. Now, results of a new survey by the American Academy of Dermatology (Academy) confirmed that the majority of people still idolize the bronzed look of a tan despite wanting to protect themselves from skin cancer.
The "Suntelligence: How Sun Smart is Your City?" online survey polled more than 7,000 adults nationwide to determine their knowledge, attitudes and behaviors toward tanning, sun protection and skin cancer detection. Twenty-six cities were ranked based on respondents' answers to several questions in each category.
"Our survey highlighted the contradictory feelings that many people have about tanning - they like the way a tan looks but are concerned about skin cancer, which is estimated to affect about one in five Americans in their lifetime," said dermatologist Zoe D. Draelos, MD, FAAD, consulting professor at Duke University School of Medicine, Durham, N.C. "What they may not realize is that no matter whether you tan or burn, a tan from the sun or tanning beds damages the skin and can cause wrinkles, age spots and skin cancer. The challenge is changing the long-standing attitudes about tanning to correlate with people's knowledge about skin cancer."
In examining the survey data, Dr. Draelos noted that 72 percent of all respondents agreed that people look more attractive with a tan. In addition, more men than women (76 percent vs. 68 percent, respectively) agreed with that statement.
Similarly, 66 percent of all respondents agreed that people look healthier with a tan. Once again more men than women (70 percent vs. 62 percent, respectively) agreed with this statement.
When asked whether or not they believed that sun exposure is good for your health, 60 percent of all respondents mistakenly agreed with this statement. Analyzing the data by gender, more men than women (62 percent vs. 58 percent, respectively) incorrectly thought that sun exposure is good for your health.
"Various reports touting the potential health benefits of sun exposure for vitamin D production are misleading people to believe that exposing oneself to UV radiation - which causes cancer - to prevent another disease is somehow beneficial," said Dr. Draelos. "In fact, the Academy does not recommend getting vitamin D from any form of UV exposure because UV radiation from the sun and tanning beds can lead to the development of skin cancer. Getting vitamin D from a healthy diet, which includes naturally enriched vitamin D foods, fortified foods and beverages, and/or vitamin supplements is a healthier alternative because it provides the exact same benefit without the skin cancer risk."
Dr. Draelos added that despite their positive attitudes about tanning, the majority of respondents expressed strong opinions on protecting themselves from skin cancer. For example, 75 percent of all respondents said they will do anything possible to prevent skin cancer. Furthermore, 80 percent of respondents expressed concern about skin cancer and feel it is important to protect themselves.
"When it comes to preventing skin cancer, actions speak louder than words," said Dr. Draelos. "So while it is encouraging that most people are concerned about skin cancer and want to reduce their risk of developing it, clearly more work needs to be done to change attitudes on tanning. If a person likes the look of a tan, he or she should consider using a self-tanner but use sunscreen with it."
May is Melanoma/Skin Cancer Detection and Prevention Month®. Visit melanomamonday to take the Academy's "Suntelligence" survey, as well as to find out how to perform a skin self-exam, download a body mole map or find free skin cancer screenings in your area.
The "Suntelligence" survey was conducted for the Academy by RH Research of Chicago from January 12 to January 31, 2010. A total of 7,116 respondents completed the online survey; more than 200 completes were conducted in each of the 26 selected MSAs (metropolitan statistical area) and an additional 1,123 completes were conducted in the U.S. outside of the MSAs. The survey's margin of error was ?±1.2 percent for national data and ?±6.9 percent for results stratified by MSA.
Source
American Academy of Dermatology (AAD)
The "Suntelligence: How Sun Smart is Your City?" online survey polled more than 7,000 adults nationwide to determine their knowledge, attitudes and behaviors toward tanning, sun protection and skin cancer detection. Twenty-six cities were ranked based on respondents' answers to several questions in each category.
"Our survey highlighted the contradictory feelings that many people have about tanning - they like the way a tan looks but are concerned about skin cancer, which is estimated to affect about one in five Americans in their lifetime," said dermatologist Zoe D. Draelos, MD, FAAD, consulting professor at Duke University School of Medicine, Durham, N.C. "What they may not realize is that no matter whether you tan or burn, a tan from the sun or tanning beds damages the skin and can cause wrinkles, age spots and skin cancer. The challenge is changing the long-standing attitudes about tanning to correlate with people's knowledge about skin cancer."
In examining the survey data, Dr. Draelos noted that 72 percent of all respondents agreed that people look more attractive with a tan. In addition, more men than women (76 percent vs. 68 percent, respectively) agreed with that statement.
Similarly, 66 percent of all respondents agreed that people look healthier with a tan. Once again more men than women (70 percent vs. 62 percent, respectively) agreed with this statement.
When asked whether or not they believed that sun exposure is good for your health, 60 percent of all respondents mistakenly agreed with this statement. Analyzing the data by gender, more men than women (62 percent vs. 58 percent, respectively) incorrectly thought that sun exposure is good for your health.
"Various reports touting the potential health benefits of sun exposure for vitamin D production are misleading people to believe that exposing oneself to UV radiation - which causes cancer - to prevent another disease is somehow beneficial," said Dr. Draelos. "In fact, the Academy does not recommend getting vitamin D from any form of UV exposure because UV radiation from the sun and tanning beds can lead to the development of skin cancer. Getting vitamin D from a healthy diet, which includes naturally enriched vitamin D foods, fortified foods and beverages, and/or vitamin supplements is a healthier alternative because it provides the exact same benefit without the skin cancer risk."
Dr. Draelos added that despite their positive attitudes about tanning, the majority of respondents expressed strong opinions on protecting themselves from skin cancer. For example, 75 percent of all respondents said they will do anything possible to prevent skin cancer. Furthermore, 80 percent of respondents expressed concern about skin cancer and feel it is important to protect themselves.
"When it comes to preventing skin cancer, actions speak louder than words," said Dr. Draelos. "So while it is encouraging that most people are concerned about skin cancer and want to reduce their risk of developing it, clearly more work needs to be done to change attitudes on tanning. If a person likes the look of a tan, he or she should consider using a self-tanner but use sunscreen with it."
May is Melanoma/Skin Cancer Detection and Prevention Month®. Visit melanomamonday to take the Academy's "Suntelligence" survey, as well as to find out how to perform a skin self-exam, download a body mole map or find free skin cancer screenings in your area.
The "Suntelligence" survey was conducted for the Academy by RH Research of Chicago from January 12 to January 31, 2010. A total of 7,116 respondents completed the online survey; more than 200 completes were conducted in each of the 26 selected MSAs (metropolitan statistical area) and an additional 1,123 completes were conducted in the U.S. outside of the MSAs. The survey's margin of error was ?±1.2 percent for national data and ?±6.9 percent for results stratified by MSA.
Source
American Academy of Dermatology (AAD)
воскресенье, 19 июня 2011 г.
Promising Results In Treating Facial Bruising From Injectables
Physicians nationwide report
promising results in treating facial bruising from injectable cosmetic
treatments by using Pinoxide(TM), an active ingredient best known for
treating under-eye circles.
Pinoxide is a proprietary blend of bicyclic monoterpene dials (BMTd)
created by AGI Dermatics and formulated in the company's Remergent
Microcirculation Therapy product. Pinoxide has been clinically proven to
speed blood flow, warm the skin, increase resistance to cold, and reduce
dark under- eye symptoms. Additional research suggests Pinoxide may also
contribute to promoting firmness and resiliency in the skin. Now,
physicians are studying the ingredient's ability to heal bruising.
Dr. Mark G. Rubin, a board-certified dermatologist currently practicing
at the Lasky Clinic in Beverly Hills, is conducting the clinical trials on
Pinoxide, applying the Microcirculation Therapy formula to the injection
site immediately after use of skin fillers such as collagen, Restylane and
Juvederm, or Botox.
"Anatomically speaking, dark circles are like bruises - so the science
behind using Pinoxide for bruising makes total sense," said Dr. Rubin. "The
skin discoloration during bruising is the result of blood leaking from
damaged blood vessels and surfacing to the skin. Similarly, blood vessels
under the eyes can burst, leading to the appearance of unattractive dark
circles."
Leading dermatologists share Dr. Rubin's opinion. Dr. Thomas Francel, a
board certified plastic surgeon, has found that application of
MicroCirculation Therapy on his patients reduces the appearance of skin
bruising, and decreases the amount of healing time for the bruise. Dr.
Francel is the Chief of Plastic Surgery at St. John's Mercy Medical Center
and an Associate Professor of Surgery at St. Louis University.
Injectable cosmetic treatments are among the five top most requested
aesthetic treatments nationwide last year. According to the American
Society for Aesthetic Plastic Surgery, more than 5 million women had
injectable cosmetic treatments last year. Bruising is a common temporary
side effect.
AGI Dermatics is the bio pharmaceutical laboratory that has led the
research of DNA repair of the skin for more than 20 years. Founded by
Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology,
dedicating research and development to DNA repair, solar impact on the
immune system, and cell-signaling in skin. The company's application of
groundbreaking active ingredients and meticulously engineered liposome
delivery systems is validated in controlled clinical studies and published
in dozens of peer-reviewed scientific and medical journals. agiderm
AGI Dermatics
agiderm
View drug information on Botox Cosmetic.
promising results in treating facial bruising from injectable cosmetic
treatments by using Pinoxide(TM), an active ingredient best known for
treating under-eye circles.
Pinoxide is a proprietary blend of bicyclic monoterpene dials (BMTd)
created by AGI Dermatics and formulated in the company's Remergent
Microcirculation Therapy product. Pinoxide has been clinically proven to
speed blood flow, warm the skin, increase resistance to cold, and reduce
dark under- eye symptoms. Additional research suggests Pinoxide may also
contribute to promoting firmness and resiliency in the skin. Now,
physicians are studying the ingredient's ability to heal bruising.
Dr. Mark G. Rubin, a board-certified dermatologist currently practicing
at the Lasky Clinic in Beverly Hills, is conducting the clinical trials on
Pinoxide, applying the Microcirculation Therapy formula to the injection
site immediately after use of skin fillers such as collagen, Restylane and
Juvederm, or Botox.
"Anatomically speaking, dark circles are like bruises - so the science
behind using Pinoxide for bruising makes total sense," said Dr. Rubin. "The
skin discoloration during bruising is the result of blood leaking from
damaged blood vessels and surfacing to the skin. Similarly, blood vessels
under the eyes can burst, leading to the appearance of unattractive dark
circles."
Leading dermatologists share Dr. Rubin's opinion. Dr. Thomas Francel, a
board certified plastic surgeon, has found that application of
MicroCirculation Therapy on his patients reduces the appearance of skin
bruising, and decreases the amount of healing time for the bruise. Dr.
Francel is the Chief of Plastic Surgery at St. John's Mercy Medical Center
and an Associate Professor of Surgery at St. Louis University.
Injectable cosmetic treatments are among the five top most requested
aesthetic treatments nationwide last year. According to the American
Society for Aesthetic Plastic Surgery, more than 5 million women had
injectable cosmetic treatments last year. Bruising is a common temporary
side effect.
AGI Dermatics is the bio pharmaceutical laboratory that has led the
research of DNA repair of the skin for more than 20 years. Founded by
Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology,
dedicating research and development to DNA repair, solar impact on the
immune system, and cell-signaling in skin. The company's application of
groundbreaking active ingredients and meticulously engineered liposome
delivery systems is validated in controlled clinical studies and published
in dozens of peer-reviewed scientific and medical journals. agiderm
AGI Dermatics
agiderm
View drug information on Botox Cosmetic.
суббота, 18 июня 2011 г.
Honey Helps Problem Wounds
A household remedy millennia old is being reinstated: honey helps the treatment of some wounds better than the most modern antibiotics. For several years now medical experts from the University of Bonn have been clocking up largely positive experience with what is known as medihoney. Even chronic wounds infected with multi-resistant bacteria often healed within a few weeks. In conjunction with colleagues from D?sseldorf, Homburg and Berlin they now want to test the experience gained in a large-scale study, as objective data on the curative properties of honey are thin on the ground.
The fact that honey can help wounds to heal is something that was known to the Ancient Egyptians several thousand years ago. And in the last two world wars poultices with honey were used to assist the healing process in soldiers' wounds. However, the rise of the new antibiotics replaced this household remedy. 'In hospitals today we are faced with germs which are resistant to almost all the current anti-biotics,' Dr. Arne Simon explains. 'As a result, the medical use of honey is becoming attractive again for the treatment of wounds.'
Dr. Simon works on the cancer ward of the Bonn University Children's Clinic. As far as the treatment of wounds is concerned, his young patients form part of a high-risk group: the medication used to treat cancer known as cytostatics not only slows down the reproduction of malignant cells, but also impairs the healing process of wounds. 'Normally a skin injury heals in a week, with our children it often takes a month or more,' he says. Moreover, children with leukaemia have a weakened immune system. If a germ enters their bloodstream via a wound, the result may be a fatal case of blood poisoning.
For several years now Bonn paediatricians have been pioneering the use in Germany of medihoney in treating wounds. Medihoney bears the CE seal for medical products; its quality is regularly tested. The success is astonishing: 'Dead tissue is rejected faster, and the wounds heals more rapidly,' Kai Sofka, wound specialist at the University Children's Clinic, emphasises. 'What is more, changing dressings is less painful, since the poultices are easier to remove without damaging the newly formed layers of skin.' Some wounds often smell unpleasant - an enormous strain on the patient. Yet honey helps here too by reducing the smell. 'Even wounds which consistently refused to heal for years can, in our experience, be brought under control with medihoney - and this frequently happens within a few weeks,' Kai Sofka says.
In the meantime two dozen hospitals in Germany are using honey in their treatment of wounds. Despite all the success there have hitherto been very few reliable clinical studies of its effectiveness. In conjunction with colleagues from D?sseldorf, Homburg and Berlin, the Bonn medical staff now want to remedy this. With the Woundpecker Data Bank, which they have developed themselves, they will be recording and evalu-ating over 100 courses of disease over the next few months. The next step planned is comparative studies with other therapeutic methods such as the very expensive cationic silver dressings. 'These too are an effective anti-bacterial method,' says Dr. Arne Simon. 'However, it is not yet clear whether the silver released from some dressings may lead to side-effects among children.' Effective bacteria killer
It has already been proved that medihoney even puts paid to multi-resistant germs such as MRSA. In this respect medihoney is neck and neck in the race to beat the antibiotic mupirocin, currently the local MRSA antibiotic of choice. This is shown by a study recently published by researchers in Australia. In one point medihoney was even superior to its rival: the bacteria did not develop any resistance to the natural product during the course of treatment.
It is also known today why honey has an antiseptic effect: when producing honey, bees add an enzyme called glucose-oxidase. This enzyme ensures that small amounts of hydrogen peroxide, an effective antiseptic, are constantly being formed from the sugar in the honey. The advantage over the hydrogen peroxide from the chemist's is that small concentrations are sufficient to kill the germs, as it is constantly being produced. As a rule much larger quantities of hydrogen peroxide would have to be used, as hydrogen peroxide loses its potency over time. However, in large concentrations it not only damages the bacteria, but also the skin cells.
Furthermore, medihoney consists of two different types of honey: one which forms a comparatively large amount of hydrogen peroxide, and another known as 'lepto-spermum honey'. Leptospermum is a species of tree which occurs in New Zealand and Australia. Honey from these trees has a particularly strong anti-bacterial effect, even in a 10% dilution. 'It is not yet known exactly why this is,' Dr. Arne Simon says. 'Probably it is a mix of phenol-type substances which come from the plant and make life particularly difficult for the bacteria in the wound.'
Contact: Dr. Arne Simon
University of Bonn
The fact that honey can help wounds to heal is something that was known to the Ancient Egyptians several thousand years ago. And in the last two world wars poultices with honey were used to assist the healing process in soldiers' wounds. However, the rise of the new antibiotics replaced this household remedy. 'In hospitals today we are faced with germs which are resistant to almost all the current anti-biotics,' Dr. Arne Simon explains. 'As a result, the medical use of honey is becoming attractive again for the treatment of wounds.'
Dr. Simon works on the cancer ward of the Bonn University Children's Clinic. As far as the treatment of wounds is concerned, his young patients form part of a high-risk group: the medication used to treat cancer known as cytostatics not only slows down the reproduction of malignant cells, but also impairs the healing process of wounds. 'Normally a skin injury heals in a week, with our children it often takes a month or more,' he says. Moreover, children with leukaemia have a weakened immune system. If a germ enters their bloodstream via a wound, the result may be a fatal case of blood poisoning.
For several years now Bonn paediatricians have been pioneering the use in Germany of medihoney in treating wounds. Medihoney bears the CE seal for medical products; its quality is regularly tested. The success is astonishing: 'Dead tissue is rejected faster, and the wounds heals more rapidly,' Kai Sofka, wound specialist at the University Children's Clinic, emphasises. 'What is more, changing dressings is less painful, since the poultices are easier to remove without damaging the newly formed layers of skin.' Some wounds often smell unpleasant - an enormous strain on the patient. Yet honey helps here too by reducing the smell. 'Even wounds which consistently refused to heal for years can, in our experience, be brought under control with medihoney - and this frequently happens within a few weeks,' Kai Sofka says.
In the meantime two dozen hospitals in Germany are using honey in their treatment of wounds. Despite all the success there have hitherto been very few reliable clinical studies of its effectiveness. In conjunction with colleagues from D?sseldorf, Homburg and Berlin, the Bonn medical staff now want to remedy this. With the Woundpecker Data Bank, which they have developed themselves, they will be recording and evalu-ating over 100 courses of disease over the next few months. The next step planned is comparative studies with other therapeutic methods such as the very expensive cationic silver dressings. 'These too are an effective anti-bacterial method,' says Dr. Arne Simon. 'However, it is not yet clear whether the silver released from some dressings may lead to side-effects among children.' Effective bacteria killer
It has already been proved that medihoney even puts paid to multi-resistant germs such as MRSA. In this respect medihoney is neck and neck in the race to beat the antibiotic mupirocin, currently the local MRSA antibiotic of choice. This is shown by a study recently published by researchers in Australia. In one point medihoney was even superior to its rival: the bacteria did not develop any resistance to the natural product during the course of treatment.
It is also known today why honey has an antiseptic effect: when producing honey, bees add an enzyme called glucose-oxidase. This enzyme ensures that small amounts of hydrogen peroxide, an effective antiseptic, are constantly being formed from the sugar in the honey. The advantage over the hydrogen peroxide from the chemist's is that small concentrations are sufficient to kill the germs, as it is constantly being produced. As a rule much larger quantities of hydrogen peroxide would have to be used, as hydrogen peroxide loses its potency over time. However, in large concentrations it not only damages the bacteria, but also the skin cells.
Furthermore, medihoney consists of two different types of honey: one which forms a comparatively large amount of hydrogen peroxide, and another known as 'lepto-spermum honey'. Leptospermum is a species of tree which occurs in New Zealand and Australia. Honey from these trees has a particularly strong anti-bacterial effect, even in a 10% dilution. 'It is not yet known exactly why this is,' Dr. Arne Simon says. 'Probably it is a mix of phenol-type substances which come from the plant and make life particularly difficult for the bacteria in the wound.'
Contact: Dr. Arne Simon
University of Bonn
пятница, 17 июня 2011 г.
New Drug For Skin Cancer Approaching Commercialization
A drug that is activated by light can be a quick, simple, and cheap treatment for tens of thousands of patients with skin cancer in Sweden alone. Researcher Leif Eriksson's team at rebro University in Sweden has now received about SEK 4 million from government research financiers, the Swedish Research Council and Vinnova, to further develop and commercialize the method.
The new drug that the rebro researchers have developed is based on the use of photo-dynamic therapy in cancer treatment. In short, this is a drug that after reorganization in the cell is activated by light, which in turn leads to chemical reactions that effectively kills cancer cells.
With this method, a majority of the some 30,000 new cases of skin cancer discovered each year in Sweden alone could be treated quickly, simply, and cost effectively. This is also true for pre-stages of skin cancer, so-called actinic keratosis.
"It's extremely gratifying that two of the most important research financiers in Sweden so actively support our research," says Leif Eriksson, professor of biophysical and theoretical chemistry at rebro University.
Leif Eriksson's drug research has grown out of the rebro Life Science Center (OLSC), an interdisciplinary, internationally acclaimed research node at rebro University. Research on new forms of treatment for skin tumors is also being conducted in collaboration with Associate Professor Lennart L?¶fgren at the Center for Head and Neck Oncology at rebro University Hospital.
"Our drug, and the new treatment concept we are developing together with researchers in Belfast, has tremendous potential. In the coming year we will also see further patents as a direct result of the collaboration with other research teams within the OLSC, including treatments for atherosclerosis and autoimmune disorders such as rheumatism," says Leif Eriksson.
The development of new drugs is being carried out with the aid of advanced computer modeling a method that has proven to be highly successful.
"We provide the expertise in the theoretical description of new drugs. In our research we aim to describe at a detailed level what they should look like, what properties they should have to match the right targets in the body, what happens if we alter the molecules in different ways, etc. We then put this together through collaboration with experimental or clinically active research teams within OLSC and at the hospital, which makes the research exciting and dynamic," says Leif Eriksson.
Vetenskapsradet (The Swedish Research Council)
vr.se
The new drug that the rebro researchers have developed is based on the use of photo-dynamic therapy in cancer treatment. In short, this is a drug that after reorganization in the cell is activated by light, which in turn leads to chemical reactions that effectively kills cancer cells.
With this method, a majority of the some 30,000 new cases of skin cancer discovered each year in Sweden alone could be treated quickly, simply, and cost effectively. This is also true for pre-stages of skin cancer, so-called actinic keratosis.
"It's extremely gratifying that two of the most important research financiers in Sweden so actively support our research," says Leif Eriksson, professor of biophysical and theoretical chemistry at rebro University.
Leif Eriksson's drug research has grown out of the rebro Life Science Center (OLSC), an interdisciplinary, internationally acclaimed research node at rebro University. Research on new forms of treatment for skin tumors is also being conducted in collaboration with Associate Professor Lennart L?¶fgren at the Center for Head and Neck Oncology at rebro University Hospital.
"Our drug, and the new treatment concept we are developing together with researchers in Belfast, has tremendous potential. In the coming year we will also see further patents as a direct result of the collaboration with other research teams within the OLSC, including treatments for atherosclerosis and autoimmune disorders such as rheumatism," says Leif Eriksson.
The development of new drugs is being carried out with the aid of advanced computer modeling a method that has proven to be highly successful.
"We provide the expertise in the theoretical description of new drugs. In our research we aim to describe at a detailed level what they should look like, what properties they should have to match the right targets in the body, what happens if we alter the molecules in different ways, etc. We then put this together through collaboration with experimental or clinically active research teams within OLSC and at the hospital, which makes the research exciting and dynamic," says Leif Eriksson.
Vetenskapsradet (The Swedish Research Council)
vr.se
Подписаться на:
Комментарии (Atom)